Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells

Baldan,Federica; Mio,Catia; Lavarone,Elisa; Di Loreto,Carla; Puglisi,Fabio; Damante,Giuseppe; Puppin,Cinzia

doi:10.3892/or.2015.3873

Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells

Authors:
- Federica Baldan
- Catia Mio
- Elisa Lavarone
- Carla Di Loreto
- Fabio Puglisi
- Giuseppe Damante
- Cinzia Puppin
View Affiliations

Affiliations: Department of Medical and Biological Sciences, University of Udine, Italy, Department of Oncology, University Hospital ‘S. Maria della Misericordia’ Udine, Italy
Published online on: March 23, 2015 https://doi.org/10.3892/or.2015.3873
Pages: 2199-2206

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Studies on stem cell differentiation led to the identification of paused genes, characterized by the contemporary presence of both activator and repressor epigenetic markers (bivalent marking). TXNIP is an oncosuppressor gene the expression of which was reduced in breast cancer. In the present study, we evaluated whether the concept of epigenetic bivalent marking can be applied to TXNIP gene in breast cancer cells. Using chromatin immunoprecipitation (ChIP), three histone modifications were investigated: two associated with transcriptional activation, lysines 9-14 acetylation of H3 histone (H3K9K14ac) and lysine 4 trimethylation of H3 histone (H3K4me3), and one associated with transcriptional silencing, lysine 27 trimethylation of H3 histone (H3K27me3). According to the bivalent marking model, TXNIP gene appears to be paused in MDA157 cells (markers of active and repressed transcription are present), but are definitively silenced in MDA468 cells (presence of only markers of transcription repression). This was proven by evaluating TXNIP mRNA and protein levels after the treatment of cell lines with a histone deacetylase inhibitor (SAHA) and a poly-ADP-ribose polymerases inhibitor (PJ34). In MDA157 cells, SAHA and PJ34 showed a synergistic effect: a large increment was observed in TXNIP mRNA and protein levels. By contrast, in MDA468 cells, synergy between the two compounds was not observed. Therefore, the pausing epigenetic signature was permissive for synergy between SAHA and PJ34 on TXNIP gene expression. The synergy between SAHA and PJ34 on TXNIP expression was associated with variation in cell viability and apoptosis. In MDA157 cells, but not in MDA468 cells, combined treatment of SAHA and PJ34 induced a decrease in cell viability and an increase of apoptosis. Thus, our data support the hypothesis that TXNIP is an effective target for the treatment of breast cancer.

View Figures

View References

1	Chen KS and DeLuca HF: Isolation and characterization of a novel cDNA from HL-60 cells treated with 1,25-dihydroxyvitamin D-3. Biochim Biophys Acta. 1219:1226–1232. 1994.
2	Kaimul AM, Nakamura H, Masutani H and Yodoi J: Thioredoxin and thioredoxin-binding protein-2 in cancer and metabolic syndrome. Free Radic Biol Med. 43:861–868. 2007. View Article : Google Scholar : PubMed/NCBI
3	Elgort MG, O’Shea JM, Jiang Y and Ayer DE: Transcriptional and translational downregulation of thioredoxin interacting protein is required for metabolic reprogramming during G(1). Genes Cancer. 1:893–907. 2010. View Article : Google Scholar
4	Patwari P, Chutkow WA, Cummings K, et al: Thioredoxin-independent regulation of metabolism by the alpha-arrestin proteins. J Biol Chem. 284:24996–25003. 2009. View Article : Google Scholar : PubMed/NCBI
5	Spindel ON, World C and Berk BC: Thioredoxin interacting protein: redox dependent and independent regulatory mechanisms. Antioxid Redox Signal. 16:587–596. 2012. View Article : Google Scholar :
6	Zhou J, Yu Q and Chng WJ: TXNIP (VDUP-1, TBP-2): a major redox regulator commonly suppressed in cancer by epigenetic mechanisms. Int J Biochem Cell Biol. 43:1668–1673. 2011. View Article : Google Scholar : PubMed/NCBI
7	Cadenas C, Franckenstein D, Schmidt M, et al: Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Res. 12:R442010. View Article : Google Scholar : PubMed/NCBI
8	Frullanti E, Colombo F, Falvella FS, et al: Association of lung adenocarcinoma clinical stage with gene expression pattern in noninvolved lung tissue. Int J Cancer. 131:E643–E648. 2012. View Article : Google Scholar : PubMed/NCBI
9	Nishizawa K, Nishiyama H, Matsui Y, et al: Thioredoxin-interacting protein suppresses bladder carcinogenesis. Carcinogenesis. 32:1459–1466. 2011. View Article : Google Scholar : PubMed/NCBI
10	Butler LM, Zhou X, Xu WS, et al: The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA. 99:11700–11705. 2002. View Article : Google Scholar : PubMed/NCBI
11	Ku WL, Girvan M, Yuan GC, Sorrentino F and Ott E: Modeling the dynamics of bivalent histone modifications. PLoS One. 8:e779442013. View Article : Google Scholar : PubMed/NCBI
12	Santos-Rosa H, Schneider R, Bannister AJ, et al: Active genes are tri-methylated at K4 of histone H3. Nature. 419:407–411. 2002. View Article : Google Scholar : PubMed/NCBI
13	Barski A, Cuddapah S, Cui K, et al: High-resolution profiling of histone methylations in the human genome. Cell. 129:823–837. 2007. View Article : Google Scholar : PubMed/NCBI
14	Chavez KJ, Garimella SV and Lipkowitz S: Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32:35–48. 2010.
15	Lavarone E, Puppin C, Passon N, Filetti S, Russo D and Damante G: The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines. Mol Cell Endocrinol. 365:1–10. 2013. View Article : Google Scholar
16	Baldan F, Lavarone E, Di Loreto C, Filetti S, Russo D, Damante G and Puppin C: Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene. Mol Biol Rep. 41:5257–5265. 2014. View Article : Google Scholar : PubMed/NCBI
17	Marks PA and Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 107:600–608. 2009. View Article : Google Scholar : PubMed/NCBI
18	Russo D, Damante G, Puxeddu E, Durante C and Filetti S: Epigenetics of thyroid cancer and novel therapeutic targets. J Mol Endocrinol. 46:R73–R81. 2011. View Article : Google Scholar : PubMed/NCBI
19	Zhou J and Chng WJ: Roles of thioredoxin binding protein (TXNIP) in oxidative stress, apoptosis and cancer. Mitochondrion. 13:163–169. 2013. View Article : Google Scholar
20	Ungerstedt JS, Sowa Y, Xu WS, et al: Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 102:673–678. 2005. View Article : Google Scholar : PubMed/NCBI
21	Chen A: PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 30:463–471. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yamaguchi F, Hirata Y, Akram H, et al: FOXO/TXNIP pathway is involved in the suppression of hepatocellular carcinoma growth by glutamate antagonist MK-801. BMC Cancer. 13:4682013. View Article : Google Scholar : PubMed/NCBI
23	Connolly R and Stearns V: Epigenetics as a therapeutic target in breast cancer. J Mammary Gland Biol Neoplasia. 17:191–204. 2012. View Article : Google Scholar : PubMed/NCBI
24	Füllgrabe J, Kavanagh E and Joseph B: Histone onco-modifications. Oncogene. 30:3391–3403. 2011. View Article : Google Scholar : PubMed/NCBI
25	Lee JM, Hays JL, Annunziata CM, et al: Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst. May 19–2014.Epub ahead of print. View Article : Google Scholar
26	Chu BF, Karpenko MJ, Liu Z, et al: Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol. 71:115–121. 2013. View Article : Google Scholar
27	Falchook GS, Fu S, Naing A, et al: Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 31:1192–1200. 2013. View Article : Google Scholar : PubMed/NCBI
28	Jasek E, Gajda M, Lis GJ, Jasińska M and Litwin JA: Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines. Anticancer Res. 34:1849–1856. 2014.PubMed/NCBI